SEC Filing Summary: Hemispherx Biopharma, Inc. (10-K)
Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Period: Fiscal year ended December 31, 2006
Industry: Biopharmaceutical
Core Business: Development and commercialization of immune system-enhancing therapies. The company's flagship products are Ampligen (experimental dsRNA for Chronic Fatigue Syndrome/ME/CFS and HIV) and Alferon N Injection (FDA-approved natural alpha interferon for genital warts). The company is currently in the process of registering a New Drug Application (NDA) with the FDA for Ampligen to treat ME/CFS.
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 Value | 2005 Value |
|---|---|---|
| Total Revenues | $933,000 | $1,083,000 |
| Net Loss | $(19,399,000) | $(12,446,000) |
| Loss Per Share (Basic/Diluted) | $(0.31) | $(0.24) |
| Research & Development Expenses | $10,127,000 | $5,218,000 |
| General & Administrative Expenses | $8,225,000 | $5,389,000 |
| Cash & Cash Equivalents | $3,646,000 | $3,827,000 |
| Short-Term Investments | $18,375,000 | $12,377,000 |
| Total Liquidity (Cash + Investments) | $22,021,000 | $16,204,000 |
| Debt (Convertible Debentures) | $3,871,000 | $4,171,000 |
| Accumulated Deficit | $(167,051,000) | $(147,652,000) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 14% to $933,000. Sales of Alferon N Injection dropped 18% due to increased competition from rival products (e.g., Aldara, Veregen). Ampligen cost-recovery sales increased slightly by 6%.
- Increased Net Loss: Net loss widened by 56% to $19.4 million. This was driven primarily by a 94% increase in R&D expenses ($4.9 million increase) related to Ampligen development and manufacturing stability studies, and a 53% increase in G&A expenses ($2.8 million increase) largely due to the adoption of FAS 123R (stock compensation) and higher accounting fees for financial restatements.
- Interest Expense Reduction: Interest and financing costs decreased by approximately $1.86 million due to reduced amortization of discounts on convertible debentures as they neared maturity.
- Manufacturing Shift: The company completed the installation of a polymer production line at its New Brunswick, NJ facility in 2006 to produce Ampligen raw materials internally, reducing reliance on third-party suppliers.
Guidance, Outlook, and Risks
- NDA Registration: The company is actively compiling data for the Ampligen NDA for ME/CFS. Management cannot provide a specific filing date due to dependencies on clinical investigators and regulatory standards. Approval is not guaranteed.
- Liquidity Outlook: As of December 31, 2006, the company held approximately $22 million in cash and short-term investments. Management believes this is sufficient to meet operating requirements for at least the next 18 to 19 months.
- Financing: The company has a Common Stock Purchase Agreement with Fusion Capital Fund II, LLC, allowing for the sale of up to $50 million of stock over 25 months. As of March 8, 2007, approximately $13.7 million had been raised under this agreement.
- Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for Ampligen would materially adversely affect operations.
- Competition: Alferon N faces significant competition from topical and injectable treatments for genital warts.
- Capital Needs: Continued substantial losses and the need for additional financing to complete clinical trials and commercialization.
- Legal Proceedings: Ongoing litigation regarding stock manipulation and disputes with former partners (e.g., Bioclones).
Investor Verification Checklist
- NDA Status: Verify the current status of the Ampligen New Drug Application (NDA) registration process and any recent FDA communications regarding the ME/CFS indication.
- Manufacturing Capacity: Confirm the operational status and regulatory compliance of the new internal polymer production line in New Brunswick and the contract manufacturing relationship with Hollister-Stier.
- Debt Covenants: Review the terms of the outstanding convertible debentures, specifically regarding the waiver obtained for the failure to maintain required Letters of Credit and the potential for liquidated damages if registration statements lapse.
- Stock Dilution: Assess the impact of the Fusion Capital Purchase Agreement and outstanding warrants/options on future share count and dilution.
- Alferon Sales Trend: Monitor quarterly sales of Alferon N Injection to determine if the decline due to competition is stabilizing or accelerating.